December 5th, 2024 “EURETINA-Brief”© Issue No. 305
Dear EURETINA Members, A very warm welcome to the December 5th, 2024 edition of EURETINA’s web-based digital periodical, “EURETINA Brief”. EURETINA are delighted to continue…
EURETINA’s
DIGITAL
NEWSLETTER
Featured Articles
1
November 21st, 2024
Latest News
December 5th, 2024 “EURETINA-Brief”© Issue No. 305
Dear EURETINA Members, A very warm welcome to the December 5th, 2024 edition of EURETINA’s…
Korean research team provide an Artificial intelligence (AI) tool for predicting the treatment response of nAMD based on OCT biomarkers.
A team of Korean researchers have published a study using an AI-model of optical coherence…
An investigation of the association between Retinitis pigmentosa (RP) and depressive disorder, including a call for practical training and methods.
Researchers at the Department of Ophthalmology, Ajou University School of Medicine, Suwon, Republic of Korea,…
The CHMP (EMA) has issued a positive opinion for the marketing authorisation of FYB203, a biosimilar candidate to Eylea (Aflibercept).
The Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA)…